- Vizgen recently announced it raised $85.2 million in Series C funding. These are the details.
Vizgen – a life science company dedicated to improving human health by visualizing single-cell spatial genomics information – announced the closing of $85.2 million Series C financing. This funding was led by Blue Water Life Science Advisors and ARCH Venture Partners. Also participating in the round were new and existing investors Sofina, Northpond Ventures, Tao Capital Partners, Novalis LifeSciences, David Walt, and others.
Vizgen announced broad U.S. availability of its MERSCOPE Platform in January 2022. And MERSCOPE is based on the MERFISH technology developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator, and the David B. Arnold, Jr. Professor of Science at Harvard University. By leveraging MERFISH’s unprecedented capability for detection efficiency and resolution, MERSCOPE is the only widely available commercial solution for high-plex single-cell spatial genomics.
KEY QUOTES:
“Single-cell spatial genomics is a true game-changer in how we are able to understand complex biological systems and it is incredibly gratifying to see how the research community is embracing our ground-breaking MERSCOPE platform for unparalleled genomics insights, accelerating biological research and discovery. Today’s financing news is a testament to the power and potential of Vizgen’s industry leading spatial genomics technology and we are still only at the cusp of what we can provide our customers in our quest to improve human health.”
— Terry Lo, President and CEO of Vizgen
“Vizgen is a visionary in spatial genomics and the demand for their technology has been immediate. They continue to lead the way in making spatial genomics a reality, providing scientists with an unprecedented view into biological systems. We are proud to play a role in Vizgen’s continued growth.”
— Nate Cornell, Managing Member of Blue Water Life Sciences
